other material
confidence high
sentiment positive
materiality 0.75
Zentalis announces positive Phase 1b data for azenosertib; plans Phase 3 trial in Cyclin E1+ ovarian cancer
Zentalis Pharmaceuticals, Inc.
- Azenosertib + paclitaxel achieved 50% ORR (7.4 months mPFS) in platinum-resistant ovarian cancer.
- Cyclin E1+ tumors showed 40% ORR vs 8.3% in Cyclin E1- (HR=0.37; p=0.0078).
- Well tolerated; Grade ≥3 AEs: thrombocytopenia (27.5%), neutropenia (25.5%), anemia (15.7%), fatigue (9.8%).
- Phase 3 study of azenosertib in combination with chemotherapy in Q1 2024.